Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-22-Speech-1-996"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Information on medicinal products (Community code relating to medicinal products) - Information on medicinal products (Community procedures for the authorisation and supervision of medicinal products) (debate)2
dcterms:Language	"et"^^xsd:language2
lpv:document identification number	"en.20101122.17.1-996"2
lpv:hasSubsequent	lp_eu:2010-11-22-Speech-1-9952
lpv:speaker	lp:Siiri Oviir2
lpv:spokenAs	member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3 unknown; Eesti Keskerakond (2009-07-14--2012-05-24)3 member; EMPL (2009-07-16--2012-01-18)3 member_of_the_bureau; ALDE (2009-07-20--2014-06-30)3 member; FEMM (2009-07-16--2012-01-18)3 vice-chair; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-29--2014-06-30)3 substitute; ECON (2009-07-16--2011-06-21)3
lpv:translated text	"I think it is a good thing that, as a result of this proposal, the focus of the directive and the regulation has moved from drug manufacturers to patients. It is extremely important to raise patients’ awareness of prescription drugs in order to prevent overconsumption of medicines as a result of commercial considerations. Unfortunately, in many Member States, it has become the norm for drug companies to lobby hard, offering a number of benefits which certainly have an influence on doctors’ decisions. Needless to say, business interests are not always consistent with the interests of patients, and this is why the amendment to Directive 2001/83/EC and Regulation (EC) No 726/2004 are necessary in order to create a clear framework for giving out information on prescription drugs. A clear framework would help to promote the rational use of drugs and would be in the interest of patients. There should certainly be clearer distinctions made between advertising and information, even though direct advertising of prescription drugs to consumers will remain prohibited under the relevant proposals."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph